Evidence map›Paper›PMID 39287607›Full record

ArticleEuropean journal of neurology2024

Stepwise dual-target magnetic resonance-guided focused ultrasound in tremor-dominant Parkinson disease: One-year follow-up.

Jui-Cheng Chen, Chun-Ming Chen, Yu Aoh, Ming-Kuei Lu, Chon-Haw Tsai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Advanced Therapeutics in Parkinson's Disease: What's New?Current neurology and neuroscience reports · 2026
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jui-Cheng ChenNeuroscience and Brain Disease Center, China Medical University, Taichung, Taiwan.ORCID 0009-0005-7146-1482
Chun-Ming ChenNeuroscience and Brain Disease Center, China Medical University, Taichung, Taiwan.
Yu AohDivision of Parkinson's Disease and Movement Disorders, Department of Neurology, China Medical University Hospital, Taichung, Taiwan.
Ming-Kuei LuNeuroscience and Brain Disease Center, China Medical University, Taichung, Taiwan.ORCID 0000-0002-2768-4399
Chon-Haw TsaiNeuroscience and Brain Disease Center, China Medical University, Taichung, Taiwan.

Funding

China Medical University Hospital DMR-110-098China Medical University Hospital DMR-111-223China Medical University Hospital DMR-113-194China Medical University Hsinchu Hospital CMUHCH-DMR-111-014China Medical University Hsinchu Hospital CMUHCH-DMR-112-002China Medical University Hsinchu Hospital CMUHCH-DMR-112-021China Medical University Hsinchu Hospital CMUHCH-DMR-113-004China Medical University Hsinchu Hospital CMUHCH-DMR113-011National Science and Technology Council MOST111-2314-B-039-073-MY2National Science and Technology Council MOST-111-2314-B-039-080-National Science and Technology Council NSTC 112-2314-B-039-004-National Science and Technology Council NSTC 113-2314-B-039-020 -
6 · The paper itself

Abstract

background and purposeMagnetic resonance-guided focused ultrasound (MRgFUS) is a nonsurgical treatment for Parkinson disease (PD). Some selected anatomical structures can be targeted by MRgFUS in PD. However, there is no uniform target yet. We have reported that stepwise dual-target MRgFUS was successfully applied to treat refractory tremors with akinetic-rigid features in PD. It generated two precise thermal ablations in the ventral intermediate nucleus (VIM) and pallidothalamic tract (PTT). Here, we report more PD patients to verify the safety and efficacy of stepwise dual-target MRgFUS.

methodsTen tremor-dominant PD patients (mean age = 66.7 ± 3.2 years, eight men) received the stepwise dual-target MRgFUS treatment with a series of primary and secondary outcome measures. The VIM and PTT were navigated based on brain magnetic resonance images. Outcome measures were categorized into primary and secondary assessments. The primary outcome measures consisted of resting tremor, action/kinetic tremor, rigidity, and bradykinesia. Secondary outcome measures encompassed non-motor symptoms scale of PD. Data collected at follow-up time points, including 1 day, 3 months, 6 months, and 1 year posttreatment, were compared with baseline data.

resultsThe severity of tremor and motor deficits represented by Clinical Rating Scale for Tremor parts A and B during off-medication status and Unified Parkinson's Disease Rating Scale III on the treated side were significantly improved (p < 0.05 by paired t-test) at 1-year follow-up. At the 1-year follow-up, significant improvement was observed in the non-motor symptoms scale. Additionally, no severe adverse effects were reported, except temporary treatment-related discomfort during the procedure.

conclusionsIn conclusion, stepwise dual-target MRgFUS emerges as a safe and effective therapeutic modality for PD patients, particularly in addressing medication-refractory tremor and akinetic-rigid syndrome.

Indexed as

Parkinson DiseaseTremorAgedFemaleFollow-Up StudiesHigh-Intensity Focused Ultrasound AblationHumansMagnetic Resonance ImagingMaleMiddle AgedTreatment OutcomeMR‐guided focused ultrasound (MRgFUS)pallidothalamic tractParkinson diseasestepwise dual‐target MRgFUSthalamotomytremorventral intermediate nucleus

Identifiers

PMID39287607
PMCPMC11555146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.